Home › Research › Disease mechanisms
Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study
Aysel Büşra Şişman, Savaş Merve, Gizem Koral, Muhammet Duran Bayar, Oğuz Yildiz, Aytül Mutlu, Vuslat Yılmaz, Erdem Tüzün et al.. Ideggyógyászati Szemle, 2025-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels. Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.
What this study adds
Evidence grade: Low
The record lists 51 participants. In this preliminary study of people with focal epilepsy, neurogranin levels were reduced in patients with treatment resistance, suggesting the protein may serve as a biomarker for monitoring seizure activity. The study is about epilepsy, not Alzheimer's disease, and does not test any treatment for Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Şişman, A. B., Merve, S., Koral, G., Bayar, M. D., Yildiz, O., Mutlu, A., et al. (2025). Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati Szemle. https://doi.org/10.18071/isz.78.0163
Vancouver
Şişman AB, Merve S, Koral G, Bayar MD, Yildiz O, Mutlu A, et al. Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati Szemle. 2025. doi:10.18071/isz.78.0163. PMID: 40476457.
BibTeX
@article{sisman2025-40476457,
author = {Şişman, Aysel Büşra and Merve, Savaş and Koral, Gizem and Bayar, Muhammet Duran and Yildiz, Oğuz and Mutlu, Aytül and Yılmaz, Vuslat and Tüzün, Erdem and others},
title = {{Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study}},
journal = {Ideggyógyászati Szemle},
year = {2025},
doi = {10.18071/isz.78.0163},
pmid = {40476457},
url = {https://doi.org/10.18071/isz.78.0163}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables.
- Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels.
- Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown.
- Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures.
- Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.
Why it matters
In this preliminary study of people with focal epilepsy, neurogranin levels were reduced in patients with treatment resistance, suggesting the protein may serve as a biomarker for monitoring seizure activity. The study is about epilepsy, not Alzheimer's disease, and does not test any treatment for Alzheimer's.
Study details
- Participants51
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Ideggyógyászati Szemle) |
| Journal's citation record | 0 / 4 | Ideggyógyászati Szemle: journal h-index 15 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 51 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Özlem Çokar: h-index 12 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Istanbul University: institution h-index 441 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40476457) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Disease mechanisms from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.